Carregando...
TMOD-03. GAINING A MECHANISTIC UNDERSTANDING OF THERAPY EVASION FROM DUAL MAPK PATHWAY INHIBITION IN A SYNGENEIC BRAFV600E MUTANT CDKN2A DELETED MOUSE MODEL TO PREEMPT RESISTANCE IN PATIENTS WITH BRAFV600E MUTANT PEDIATRIC GLIOMA
Pediatric patients with gliomas expressing the constitutively active BRAF(V600E)-mutant kinase are candidates for clinical trials for small molecule inhibitors specific for BRAF(V600E) (BRAFi) and MEK (MEKi) (Grossauer et al; Oncotarget 2016, 15:75839). Clinical results from combined BRAF and MEK in...
Na minha lista:
Publicado no: | Neuro Oncol |
---|---|
Principais autores: | , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Oxford University Press
2019
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6477238/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.242 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|